| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Expenditures | 17 | 2018 | 2387 | 1.540 |
Why?
|
| Cost-Benefit Analysis | 62 | 2016 | 5526 | 1.530 |
Why?
|
| Health Care Costs | 18 | 2014 | 3242 | 1.070 |
Why?
|
| Comparative Effectiveness Research | 4 | 2011 | 714 | 0.980 |
Why?
|
| Medicare | 14 | 2018 | 6823 | 0.930 |
Why?
|
| Technology Assessment, Biomedical | 7 | 2007 | 312 | 0.930 |
Why?
|
| Quality-Adjusted Life Years | 29 | 2016 | 1737 | 0.690 |
Why?
|
| Health Services Research | 8 | 2009 | 1808 | 0.680 |
Why?
|
| Biomedical Technology | 5 | 2006 | 210 | 0.680 |
Why?
|
| Diffusion of Innovation | 4 | 2016 | 721 | 0.630 |
Why?
|
| Natural Language Processing | 4 | 2009 | 1203 | 0.610 |
Why?
|
| Colectomy | 2 | 2012 | 697 | 0.540 |
Why?
|
| Markov Chains | 15 | 2016 | 968 | 0.510 |
Why?
|
| Cost Control | 4 | 2013 | 624 | 0.500 |
Why?
|
| Economic Competition | 2 | 2016 | 223 | 0.500 |
Why?
|
| Mass Screening | 18 | 2006 | 5446 | 0.480 |
Why?
|
| Defibrillators, Implantable | 6 | 2010 | 1490 | 0.470 |
Why?
|
| Health Policy | 10 | 2016 | 2698 | 0.470 |
Why?
|
| Information Storage and Retrieval | 3 | 2009 | 834 | 0.460 |
Why?
|
| United States | 63 | 2018 | 72903 | 0.430 |
Why?
|
| Vaginal Smears | 4 | 2001 | 513 | 0.430 |
Why?
|
| Hypercholesterolemia | 7 | 2000 | 1149 | 0.430 |
Why?
|
| Industry | 2 | 2006 | 362 | 0.430 |
Why?
|
| Drug Industry | 3 | 2009 | 791 | 0.420 |
Why?
|
| Cholesterol | 8 | 2000 | 2898 | 0.420 |
Why?
|
| Drug Approval | 3 | 2009 | 818 | 0.420 |
Why?
|
| Evidence-Based Medicine | 6 | 2005 | 3685 | 0.410 |
Why?
|
| Multimedia | 5 | 2005 | 76 | 0.400 |
Why?
|
| Utilization Review | 2 | 2005 | 381 | 0.400 |
Why?
|
| Sulfonylurea Compounds | 2 | 2011 | 221 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2016 | 10383 | 0.390 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2018 | 1568 | 0.390 |
Why?
|
| Gaucher Disease | 7 | 1998 | 110 | 0.380 |
Why?
|
| Coronary Disease | 14 | 2000 | 5912 | 0.370 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2011 | 373 | 0.370 |
Why?
|
| Reimbursement, Incentive | 4 | 2013 | 541 | 0.370 |
Why?
|
| Mesalamine | 1 | 2011 | 134 | 0.360 |
Why?
|
| Colonic Pouches | 1 | 2012 | 122 | 0.360 |
Why?
|
| Health Care Reform | 5 | 2016 | 1259 | 0.350 |
Why?
|
| Decision Making | 4 | 2011 | 3965 | 0.350 |
Why?
|
| Kyphoplasty | 1 | 2011 | 45 | 0.350 |
Why?
|
| Organizational Policy | 5 | 2008 | 434 | 0.350 |
Why?
|
| Technology, High-Cost | 1 | 2010 | 32 | 0.340 |
Why?
|
| Azathioprine | 1 | 2011 | 350 | 0.340 |
Why?
|
| Low Back Pain | 1 | 2018 | 987 | 0.340 |
Why?
|
| Vertebroplasty | 1 | 2011 | 78 | 0.340 |
Why?
|
| Androgen Antagonists | 3 | 2012 | 1411 | 0.340 |
Why?
|
| Colitis, Ulcerative | 2 | 2012 | 1915 | 0.330 |
Why?
|
| Health Services | 3 | 2013 | 756 | 0.330 |
Why?
|
| Private Sector | 3 | 2013 | 396 | 0.330 |
Why?
|
| Insurance Coverage | 4 | 2008 | 1944 | 0.320 |
Why?
|
| Academies and Institutes | 1 | 2011 | 326 | 0.320 |
Why?
|
| Watchful Waiting | 2 | 2012 | 493 | 0.320 |
Why?
|
| Osteoporosis | 2 | 2011 | 1582 | 0.320 |
Why?
|
| Decision Support Techniques | 16 | 2014 | 2003 | 0.320 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2012 | 784 | 0.320 |
Why?
|
| Myocardial Infarction | 10 | 2014 | 11499 | 0.310 |
Why?
|
| Capsule Endoscopy | 1 | 2009 | 107 | 0.300 |
Why?
|
| Glucosylceramidase | 4 | 1994 | 124 | 0.300 |
Why?
|
| Device Approval | 1 | 2010 | 164 | 0.300 |
Why?
|
| Insurance Claim Reporting | 2 | 2008 | 166 | 0.300 |
Why?
|
| Equipment and Supplies | 2 | 2010 | 273 | 0.290 |
Why?
|
| Taxes | 1 | 2010 | 219 | 0.290 |
Why?
|
| Fast Foods | 1 | 2010 | 220 | 0.290 |
Why?
|
| Hypoglycemic Agents | 7 | 2014 | 3110 | 0.290 |
Why?
|
| Prostatectomy | 2 | 2012 | 1782 | 0.280 |
Why?
|
| Decision Making, Organizational | 2 | 2004 | 136 | 0.280 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 1999 | 345 | 0.280 |
Why?
|
| Preimplantation Diagnosis | 1 | 2009 | 143 | 0.280 |
Why?
|
| Tomography | 1 | 2009 | 443 | 0.270 |
Why?
|
| Pattern Recognition, Automated | 2 | 2009 | 978 | 0.260 |
Why?
|
| Government Regulation | 2 | 2010 | 525 | 0.260 |
Why?
|
| Sodium, Dietary | 1 | 2010 | 426 | 0.260 |
Why?
|
| Humans | 136 | 2018 | 765968 | 0.260 |
Why?
|
| Nutrition Policy | 1 | 2010 | 467 | 0.260 |
Why?
|
| Cystic Fibrosis | 3 | 2009 | 1287 | 0.250 |
Why?
|
| Delivery of Health Care | 4 | 2016 | 5370 | 0.250 |
Why?
|
| Alendronate | 1 | 2006 | 174 | 0.240 |
Why?
|
| Efficiency | 2 | 2008 | 480 | 0.240 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 682 | 0.240 |
Why?
|
| Insurance, Health | 4 | 2008 | 2521 | 0.240 |
Why?
|
| Models, Econometric | 4 | 2011 | 213 | 0.240 |
Why?
|
| Terminally Ill | 1 | 2007 | 241 | 0.230 |
Why?
|
| Costs and Cost Analysis | 13 | 2010 | 1668 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 3 | 2012 | 9249 | 0.230 |
Why?
|
| Long-Term Care | 2 | 2004 | 629 | 0.230 |
Why?
|
| Spinal Fractures | 1 | 2011 | 703 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2001 | 2047 | 0.230 |
Why?
|
| Insurance Claim Review | 2 | 2008 | 746 | 0.220 |
Why?
|
| Teriparatide | 1 | 2006 | 225 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2014 | 12240 | 0.220 |
Why?
|
| Terminal Care | 2 | 2007 | 1774 | 0.220 |
Why?
|
| Intestine, Small | 1 | 2009 | 1214 | 0.210 |
Why?
|
| Protein C | 1 | 2003 | 134 | 0.210 |
Why?
|
| Disease | 1 | 2008 | 676 | 0.210 |
Why?
|
| Activities of Daily Living | 4 | 2008 | 2415 | 0.200 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2004 | 170 | 0.200 |
Why?
|
| Monte Carlo Method | 5 | 2014 | 1238 | 0.200 |
Why?
|
| Infertility, Female | 1 | 2008 | 763 | 0.200 |
Why?
|
| Heart Arrest | 2 | 2003 | 1516 | 0.200 |
Why?
|
| Prostatic Neoplasms | 4 | 2012 | 11083 | 0.200 |
Why?
|
| Aged | 48 | 2018 | 171117 | 0.190 |
Why?
|
| Sensitivity and Specificity | 20 | 2010 | 14652 | 0.190 |
Why?
|
| Reimbursement Mechanisms | 1 | 2007 | 672 | 0.190 |
Why?
|
| Orphan Drug Production | 2 | 1992 | 48 | 0.190 |
Why?
|
| Heparin | 2 | 1999 | 1630 | 0.190 |
Why?
|
| Drug Costs | 3 | 2013 | 1193 | 0.190 |
Why?
|
| Research Support as Topic | 3 | 2011 | 696 | 0.190 |
Why?
|
| Blood Glucose | 4 | 2014 | 6424 | 0.190 |
Why?
|
| Tibial Fractures | 1 | 2004 | 276 | 0.190 |
Why?
|
| Orchiectomy | 2 | 2000 | 460 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 1458 | 0.190 |
Why?
|
| Terminology as Topic | 1 | 2008 | 1534 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2009 | 1064 | 0.180 |
Why?
|
| Angioplasty | 2 | 2014 | 352 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 5 | 2005 | 7425 | 0.180 |
Why?
|
| Financing, Personal | 2 | 2013 | 310 | 0.180 |
Why?
|
| Quality of Life | 11 | 2012 | 13462 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 1084 | 0.180 |
Why?
|
| Streptococcus agalactiae | 1 | 2002 | 328 | 0.180 |
Why?
|
| Diethylstilbestrol | 1 | 2000 | 84 | 0.180 |
Why?
|
| Thiazolidinediones | 2 | 2014 | 459 | 0.180 |
Why?
|
| Aircraft | 1 | 2001 | 135 | 0.170 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2002 | 216 | 0.170 |
Why?
|
| Laparoscopy | 2 | 2011 | 2039 | 0.170 |
Why?
|
| California | 8 | 2008 | 1436 | 0.170 |
Why?
|
| Body Weight | 1 | 2011 | 4622 | 0.170 |
Why?
|
| Endometriosis | 1 | 2008 | 870 | 0.170 |
Why?
|
| Models, Economic | 3 | 2013 | 716 | 0.170 |
Why?
|
| Influenza Vaccines | 3 | 2014 | 778 | 0.170 |
Why?
|
| Influenza, Human | 4 | 2014 | 1539 | 0.170 |
Why?
|
| Venous Thrombosis | 2 | 1999 | 1327 | 0.160 |
Why?
|
| Managed Care Programs | 1 | 2004 | 934 | 0.160 |
Why?
|
| Intensive Care Units | 3 | 2008 | 3800 | 0.160 |
Why?
|
| Bone Density Conservation Agents | 1 | 2006 | 791 | 0.160 |
Why?
|
| Cataract Extraction | 1 | 2003 | 464 | 0.150 |
Why?
|
| Research | 3 | 2011 | 1975 | 0.150 |
Why?
|
| Ultraviolet Therapy | 1 | 1998 | 81 | 0.150 |
Why?
|
| Electric Countershock | 1 | 2001 | 534 | 0.150 |
Why?
|
| Mass Vaccination | 2 | 2009 | 111 | 0.150 |
Why?
|
| Biological Products | 1 | 2007 | 942 | 0.150 |
Why?
|
| Anticoagulants | 4 | 2016 | 4862 | 0.150 |
Why?
|
| Health Care Rationing | 1 | 2001 | 436 | 0.150 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 617 | 0.150 |
Why?
|
| Age Factors | 9 | 2018 | 18380 | 0.140 |
Why?
|
| Female | 61 | 2018 | 396112 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2004 | 1282 | 0.140 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 2966 | 0.140 |
Why?
|
| Male | 57 | 2018 | 363698 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 3413 | 0.140 |
Why?
|
| Caregivers | 2 | 2011 | 2307 | 0.140 |
Why?
|
| Attitude to Health | 3 | 2008 | 2020 | 0.140 |
Why?
|
| Crohn Disease | 1 | 2009 | 2283 | 0.140 |
Why?
|
| Life Expectancy | 6 | 2013 | 1247 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 4 | 2008 | 2172 | 0.130 |
Why?
|
| Interviews as Topic | 5 | 2005 | 2739 | 0.130 |
Why?
|
| Survival Analysis | 7 | 2007 | 10070 | 0.130 |
Why?
|
| State Medicine | 2 | 2008 | 219 | 0.130 |
Why?
|
| Government Agencies | 1 | 1996 | 161 | 0.130 |
Why?
|
| Decision Trees | 6 | 2016 | 509 | 0.130 |
Why?
|
| Receptor, erbB-2 | 1 | 2007 | 2593 | 0.130 |
Why?
|
| Disease Outbreaks | 3 | 2010 | 1759 | 0.130 |
Why?
|
| Stroke | 5 | 2016 | 9747 | 0.130 |
Why?
|
| Financing, Government | 2 | 2009 | 473 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 6069 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2000 | 1534 | 0.120 |
Why?
|
| Publishing | 1 | 2002 | 835 | 0.120 |
Why?
|
| Geriatric Assessment | 5 | 2008 | 1429 | 0.120 |
Why?
|
| Quality of Health Care | 3 | 2010 | 4300 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 6493 | 0.120 |
Why?
|
| Medical Informatics | 1 | 2002 | 745 | 0.120 |
Why?
|
| Software | 5 | 2008 | 4462 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 1998 | 315 | 0.120 |
Why?
|
| Hyperlipidemias | 2 | 2002 | 770 | 0.110 |
Why?
|
| Hospitals, Veterans | 1 | 1996 | 395 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 2780 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1145 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2018 | 7838 | 0.110 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 2659 | 0.110 |
Why?
|
| Hypolipidemic Agents | 1 | 1998 | 608 | 0.110 |
Why?
|
| Treatment Outcome | 18 | 2014 | 65188 | 0.110 |
Why?
|
| Brachytherapy | 2 | 2012 | 1222 | 0.110 |
Why?
|
| Coronary Angiography | 2 | 2010 | 4493 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 2268 | 0.110 |
Why?
|
| Health Services for the Aged | 2 | 2004 | 265 | 0.110 |
Why?
|
| Hospital Costs | 3 | 2007 | 956 | 0.110 |
Why?
|
| Renal Dialysis | 3 | 2008 | 1799 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2006 | 934 | 0.100 |
Why?
|
| Visual Acuity | 1 | 2003 | 2708 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2000 | 970 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2002 | 1206 | 0.100 |
Why?
|
| Middle Aged | 33 | 2013 | 223009 | 0.100 |
Why?
|
| Survivors | 1 | 2003 | 2372 | 0.100 |
Why?
|
| Attitude to Computers | 2 | 2005 | 196 | 0.100 |
Why?
|
| Human Growth Hormone | 2 | 2008 | 638 | 0.100 |
Why?
|
| Atrial Appendage | 1 | 2016 | 284 | 0.100 |
Why?
|
| Public Policy | 1 | 1996 | 551 | 0.100 |
Why?
|
| Risk Factors | 20 | 2018 | 74840 | 0.100 |
Why?
|
| Cost of Illness | 4 | 2012 | 1950 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 3251 | 0.100 |
Why?
|
| Prenatal Diagnosis | 2 | 1991 | 1268 | 0.100 |
Why?
|
| Methotrexate | 1 | 1998 | 1722 | 0.100 |
Why?
|
| Health Status Indicators | 3 | 2008 | 966 | 0.100 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 151 | 0.090 |
Why?
|
| Coronary Artery Bypass | 3 | 2014 | 2186 | 0.090 |
Why?
|
| Hospitals | 1 | 2005 | 3888 | 0.090 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2011 | 72 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2011 | 3475 | 0.090 |
Why?
|
| Choice Behavior | 1 | 1997 | 844 | 0.090 |
Why?
|
| Geography | 1 | 2013 | 652 | 0.090 |
Why?
|
| Pravastatin | 1 | 2013 | 391 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 8529 | 0.090 |
Why?
|
| Genetic Testing | 3 | 2006 | 3595 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 1672 | 0.090 |
Why?
|
| Psoriasis | 1 | 1998 | 919 | 0.090 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 59489 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2002 | 2187 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2005 | 5508 | 0.090 |
Why?
|
| beta-Alanine | 1 | 2010 | 83 | 0.090 |
Why?
|
| Sex Factors | 5 | 2018 | 10603 | 0.090 |
Why?
|
| Life Support Care | 1 | 2011 | 226 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 1997 | 1470 | 0.080 |
Why?
|
| Nephrons | 1 | 2011 | 165 | 0.080 |
Why?
|
| Jurisprudence | 1 | 2010 | 109 | 0.080 |
Why?
|
| Adult | 29 | 2010 | 223044 | 0.080 |
Why?
|
| Risk | 3 | 2018 | 9591 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 1997 | 861 | 0.080 |
Why?
|
| Expressed Emotion | 1 | 2010 | 93 | 0.080 |
Why?
|
| Equipment Failure | 2 | 2010 | 578 | 0.080 |
Why?
|
| Eligibility Determination | 1 | 2013 | 423 | 0.080 |
Why?
|
| Sepsis | 1 | 2003 | 2606 | 0.080 |
Why?
|
| Diabetes Complications | 2 | 2014 | 1316 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 21056 | 0.080 |
Why?
|
| Subject Headings | 1 | 2008 | 16 | 0.080 |
Why?
|
| Antihypertensive Agents | 2 | 1998 | 2033 | 0.080 |
Why?
|
| Electrocardiography | 3 | 1999 | 6404 | 0.080 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 134 | 0.080 |
Why?
|
| Probability | 3 | 2003 | 2475 | 0.080 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2009 | 117 | 0.080 |
Why?
|
| Public Health | 1 | 2002 | 2680 | 0.080 |
Why?
|
| Object Attachment | 1 | 2011 | 329 | 0.080 |
Why?
|
| Physicians | 2 | 2004 | 4588 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2018 | 2116 | 0.080 |
Why?
|
| Drug Resistance, Microbial | 2 | 1989 | 833 | 0.070 |
Why?
|
| Pregnancy, Multiple | 1 | 2009 | 216 | 0.070 |
Why?
|
| Drugs, Generic | 2 | 2014 | 456 | 0.070 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2010 | 291 | 0.070 |
Why?
|
| Psychometrics | 1 | 1998 | 3062 | 0.070 |
Why?
|
| Observation | 1 | 2010 | 309 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2005 | 12056 | 0.070 |
Why?
|
| Twins | 1 | 2009 | 341 | 0.070 |
Why?
|
| Gastrointestinal Agents | 1 | 2012 | 510 | 0.070 |
Why?
|
| Standard of Care | 1 | 2011 | 567 | 0.070 |
Why?
|
| Logistic Models | 4 | 2010 | 13266 | 0.070 |
Why?
|
| Coronary Artery Disease | 3 | 2014 | 6544 | 0.070 |
Why?
|
| Hypoglycemia | 2 | 2010 | 896 | 0.070 |
Why?
|
| Exercise Test | 2 | 1999 | 2180 | 0.070 |
Why?
|
| Athletic Performance | 1 | 2008 | 112 | 0.070 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 1998 | 147 | 0.070 |
Why?
|
| Forecasting | 3 | 2011 | 2936 | 0.070 |
Why?
|
| Warfarin | 2 | 2016 | 1494 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 1998 | 2084 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 3 | 2013 | 2495 | 0.070 |
Why?
|
| Echocardiography | 1 | 1999 | 5045 | 0.070 |
Why?
|
| Health Services Needs and Demand | 2 | 2004 | 1406 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2007 | 1600 | 0.060 |
Why?
|
| Blastocyst | 1 | 2009 | 432 | 0.060 |
Why?
|
| Pregnancy Rate | 1 | 2009 | 655 | 0.060 |
Why?
|
| Public Sector | 1 | 2007 | 264 | 0.060 |
Why?
|
| Computer Literacy | 2 | 2005 | 44 | 0.060 |
Why?
|
| Canada | 2 | 2008 | 2119 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2011 | 927 | 0.060 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2009 | 452 | 0.060 |
Why?
|
| Clinical Trials as Topic | 5 | 2014 | 8041 | 0.060 |
Why?
|
| Heart Diseases | 3 | 2002 | 2821 | 0.060 |
Why?
|
| Anthrax Vaccines | 1 | 2005 | 13 | 0.060 |
Why?
|
| Hospitalization | 4 | 2013 | 10808 | 0.060 |
Why?
|
| Exercise | 4 | 2008 | 5937 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2010 | 864 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2010 | 697 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2010 | 870 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 1991 | 1441 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2010 | 6322 | 0.060 |
Why?
|
| Algorithms | 4 | 2009 | 14071 | 0.060 |
Why?
|
| Atrial Fibrillation | 2 | 2016 | 5189 | 0.060 |
Why?
|
| Anthrax | 1 | 2005 | 83 | 0.060 |
Why?
|
| Geriatric Nursing | 1 | 2005 | 39 | 0.060 |
Why?
|
| Disease Progression | 4 | 2013 | 13632 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2010 | 6255 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2009 | 995 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 3529 | 0.060 |
Why?
|
| Models, Cardiovascular | 1 | 2010 | 978 | 0.060 |
Why?
|
| Bioterrorism | 1 | 2005 | 144 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2011 | 12437 | 0.060 |
Why?
|
| Direct Service Costs | 2 | 2014 | 61 | 0.060 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2009 | 618 | 0.060 |
Why?
|
| Rate Setting and Review | 1 | 2004 | 41 | 0.060 |
Why?
|
| Health Facility Merger | 1 | 2004 | 47 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2000 | 1133 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2009 | 536 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 1997 | 3076 | 0.060 |
Why?
|
| Economics | 1 | 2004 | 141 | 0.060 |
Why?
|
| Recurrence | 4 | 2000 | 8501 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 464 | 0.050 |
Why?
|
| Time Factors | 6 | 2013 | 40065 | 0.050 |
Why?
|
| Physician Executives | 1 | 2004 | 140 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2014 | 3564 | 0.050 |
Why?
|
| Commerce | 1 | 2009 | 611 | 0.050 |
Why?
|
| Capitation Fee | 1 | 2004 | 115 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4850 | 0.050 |
Why?
|
| Patient Care | 1 | 2009 | 629 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2007 | 916 | 0.050 |
Why?
|
| Japan | 1 | 2008 | 1415 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 15652 | 0.050 |
Why?
|
| Genes, BRCA2 | 1 | 2006 | 588 | 0.050 |
Why?
|
| APACHE | 1 | 2003 | 268 | 0.050 |
Why?
|
| Hypertension | 4 | 2013 | 8626 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1566 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2007 | 41649 | 0.050 |
Why?
|
| Myocardial Revascularization | 2 | 2003 | 793 | 0.050 |
Why?
|
| Genes, BRCA1 | 1 | 2006 | 750 | 0.050 |
Why?
|
| Pregnancy | 4 | 2009 | 30260 | 0.050 |
Why?
|
| Heterozygote | 1 | 2009 | 2794 | 0.050 |
Why?
|
| Affect | 1 | 2010 | 1500 | 0.050 |
Why?
|
| New York City | 1 | 2004 | 733 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 1996 | 791 | 0.050 |
Why?
|
| Fee-for-Service Plans | 2 | 2004 | 716 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2005 | 382 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20659 | 0.050 |
Why?
|
| Mortality | 3 | 1999 | 2904 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 2770 | 0.050 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2011 | 1188 | 0.050 |
Why?
|
| Pyrazines | 1 | 2007 | 1204 | 0.050 |
Why?
|
| Patient Selection | 2 | 2013 | 4255 | 0.050 |
Why?
|
| Developed Countries | 1 | 2004 | 452 | 0.050 |
Why?
|
| Reproducibility of Results | 7 | 2005 | 20124 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 6309 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1387 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2009 | 1306 | 0.050 |
Why?
|
| Acute Coronary Syndrome | 1 | 2014 | 2184 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2010 | 2080 | 0.040 |
Why?
|
| Europe | 1 | 2008 | 3423 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 2023 | 0.040 |
Why?
|
| Survival Rate | 4 | 2016 | 12795 | 0.040 |
Why?
|
| Bacteria | 2 | 1989 | 2209 | 0.040 |
Why?
|
| Cross Infection | 1 | 1989 | 1427 | 0.040 |
Why?
|
| Radiography | 2 | 2009 | 6919 | 0.040 |
Why?
|
| Data Collection | 2 | 2002 | 3318 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 1989 | 7478 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 1999 | 6203 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2263 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 644 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2002 | 533 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 2002 | 317 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 1984 | 1158 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1994 | 3446 | 0.040 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 135 | 0.040 |
Why?
|
| Dipyridamole | 1 | 1999 | 137 | 0.040 |
Why?
|
| Acute Disease | 2 | 2008 | 7232 | 0.040 |
Why?
|
| Dobutamine | 1 | 1999 | 114 | 0.040 |
Why?
|
| Self Concept | 1 | 2005 | 1037 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1999 | 185 | 0.040 |
Why?
|
| Hemorrhage | 3 | 2014 | 3461 | 0.040 |
Why?
|
| Schizophrenia | 1 | 1997 | 6972 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36532 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2004 | 1138 | 0.040 |
Why?
|
| Medicare Part C | 1 | 2004 | 335 | 0.040 |
Why?
|
| Histamine H2 Antagonists | 1 | 2000 | 168 | 0.040 |
Why?
|
| Benchmarking | 1 | 2005 | 1052 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 3537 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2009 | 8923 | 0.040 |
Why?
|
| Synostosis | 1 | 1998 | 45 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2006 | 1084 | 0.040 |
Why?
|
| Comorbidity | 2 | 2013 | 10563 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2003 | 1816 | 0.040 |
Why?
|
| Cities | 2 | 2014 | 543 | 0.040 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1997 | 63 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2788 | 0.040 |
Why?
|
| Primary Prevention | 2 | 2013 | 1187 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2424 | 0.040 |
Why?
|
| Incidence | 3 | 2013 | 21480 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2005 | 5089 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2002 | 15398 | 0.030 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1997 | 118 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2002 | 805 | 0.030 |
Why?
|
| Cost Allocation | 1 | 1996 | 47 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1998 | 416 | 0.030 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1997 | 164 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 2 | 2002 | 1310 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 1727 | 0.030 |
Why?
|
| Universities | 1 | 2002 | 998 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2007 | 2098 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 6832 | 0.030 |
Why?
|
| Child | 6 | 2011 | 80564 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2007 | 24282 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2005 | 2247 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1997 | 208 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2008 | 1946 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1999 | 538 | 0.030 |
Why?
|
| Pain | 1 | 2011 | 5077 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 3181 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 3 | 1996 | 1370 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2001 | 790 | 0.030 |
Why?
|
| Travel | 1 | 2001 | 806 | 0.030 |
Why?
|
| Mammography | 1 | 2006 | 2423 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2002 | 946 | 0.030 |
Why?
|
| Septal Occluder Device | 1 | 2016 | 127 | 0.030 |
Why?
|
| Prognosis | 3 | 2007 | 29922 | 0.030 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2000 | 394 | 0.030 |
Why?
|
| Quality Control | 1 | 1998 | 837 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 1978 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 1997 | 2844 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 10729 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1999 | 988 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2000 | 553 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 15880 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 4274 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2010 | 8532 | 0.030 |
Why?
|
| Pandemics | 1 | 2014 | 8703 | 0.030 |
Why?
|
| Hygiene | 1 | 2014 | 95 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2002 | 2761 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2003 | 2267 | 0.030 |
Why?
|
| Audiovisual Aids | 1 | 1994 | 98 | 0.030 |
Why?
|
| Income | 2 | 1999 | 1874 | 0.030 |
Why?
|
| National Health Programs | 1 | 1997 | 443 | 0.030 |
Why?
|
| Patient Isolation | 1 | 2014 | 101 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2009 | 3458 | 0.030 |
Why?
|
| Health Status | 2 | 2004 | 4080 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2007 | 11868 | 0.030 |
Why?
|
| Genomics | 1 | 2009 | 5929 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1996 | 1006 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1998 | 2341 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2007 | 5343 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 1994 | 246 | 0.030 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 246 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2008 | 8067 | 0.030 |
Why?
|
| Vaccination | 1 | 2005 | 3426 | 0.030 |
Why?
|
| Reference Values | 1 | 2000 | 4908 | 0.030 |
Why?
|
| Inpatients | 1 | 2004 | 2564 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2000 | 833 | 0.020 |
Why?
|
| Proportional Hazards Models | 3 | 2003 | 12509 | 0.020 |
Why?
|
| Insulin | 1 | 2007 | 6599 | 0.020 |
Why?
|
| Insurance Benefits | 1 | 1994 | 186 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 11206 | 0.020 |
Why?
|
| Stents | 1 | 2003 | 3213 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 1 | 1997 | 557 | 0.020 |
Why?
|
| Models, Biological | 1 | 1987 | 9443 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2014 | 440 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2003 | 9649 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2000 | 2464 | 0.020 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 1991 | 85 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 1237 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1995 | 1053 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 1997 | 1648 | 0.020 |
Why?
|
| Health Education | 1 | 1997 | 1060 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 766 | 0.020 |
Why?
|
| Patient Admission | 1 | 1997 | 1365 | 0.020 |
Why?
|
| Iopamidol | 1 | 2010 | 188 | 0.020 |
Why?
|
| Adolescent | 6 | 2010 | 88835 | 0.020 |
Why?
|
| Thiophenes | 1 | 2014 | 569 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 2 | 1997 | 445 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2014 | 731 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 3715 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2013 | 81514 | 0.020 |
Why?
|
| Adenosine | 1 | 2014 | 806 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2014 | 560 | 0.020 |
Why?
|
| Body Composition | 2 | 2008 | 2439 | 0.020 |
Why?
|
| Aging | 1 | 2007 | 8731 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1989 | 275 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2009 | 264 | 0.020 |
Why?
|
| Life Style | 3 | 2007 | 3926 | 0.020 |
Why?
|
| Abortion, Eugenic | 1 | 1987 | 39 | 0.020 |
Why?
|
| Immunization Programs | 1 | 2009 | 267 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2008 | 163 | 0.020 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 1987 | 119 | 0.020 |
Why?
|
| Cholesterol, LDL | 2 | 2002 | 2393 | 0.020 |
Why?
|
| Insulin, Long-Acting | 1 | 2007 | 59 | 0.020 |
Why?
|
| Attitude | 1 | 2011 | 770 | 0.020 |
Why?
|
| Research Design | 2 | 1999 | 6209 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2011 | 479 | 0.020 |
Why?
|
| Cardiology | 1 | 1997 | 1702 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 2598 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 390 | 0.020 |
Why?
|
| Prevalence | 3 | 2010 | 15842 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1998 | 8733 | 0.020 |
Why?
|
| Intracranial Hemorrhages | 1 | 2010 | 814 | 0.010 |
Why?
|
| Community Health Services | 1 | 2010 | 657 | 0.010 |
Why?
|
| Societies, Medical | 1 | 1997 | 3956 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2004 | 366 | 0.010 |
Why?
|
| Insurance Selection Bias | 1 | 2004 | 69 | 0.010 |
Why?
|
| Seasons | 1 | 2009 | 1524 | 0.010 |
Why?
|
| Attitude of Health Personnel | 2 | 1990 | 3925 | 0.010 |
Why?
|
| Genotype | 2 | 2014 | 13024 | 0.010 |
Why?
|
| Muscle Strength | 1 | 2008 | 637 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 4247 | 0.010 |
Why?
|
| Piperazines | 1 | 2014 | 2549 | 0.010 |
Why?
|
| Prospective Payment System | 1 | 1984 | 135 | 0.010 |
Why?
|
| Demography | 1 | 1988 | 1641 | 0.010 |
Why?
|
| Alleles | 1 | 2014 | 6897 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6499 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 9373 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 26346 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2005 | 656 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 1326 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2005 | 399 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 30198 | 0.010 |
Why?
|
| Longevity | 1 | 1989 | 1087 | 0.010 |
Why?
|
| Educational Status | 1 | 2008 | 2513 | 0.010 |
Why?
|
| Coronary Restenosis | 1 | 2003 | 396 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2002 | 471 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 2652 | 0.010 |
Why?
|
| Risk Adjustment | 1 | 2004 | 596 | 0.010 |
Why?
|
| Weight Gain | 1 | 2010 | 2355 | 0.010 |
Why?
|
| Antacids | 1 | 2000 | 94 | 0.010 |
Why?
|
| Heartburn | 1 | 2000 | 71 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 4015 | 0.010 |
Why?
|
| Goserelin | 1 | 1999 | 126 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2005 | 1405 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 18071 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 2000 | 398 | 0.010 |
Why?
|
| Manitoba | 1 | 1997 | 24 | 0.010 |
Why?
|
| Lod Score | 1 | 1998 | 598 | 0.010 |
Why?
|
| Leuprolide | 1 | 1999 | 312 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2009 | 3050 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2006 | 54802 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 5329 | 0.010 |
Why?
|
| Value of Life | 1 | 1997 | 97 | 0.010 |
Why?
|
| Michigan | 1 | 1997 | 328 | 0.010 |
Why?
|
| Joints | 1 | 1998 | 321 | 0.010 |
Why?
|
| Lipids | 1 | 2007 | 3315 | 0.010 |
Why?
|
| Leisure Activities | 1 | 1997 | 310 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 1984 | 1219 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1998 | 856 | 0.010 |
Why?
|
| Medicaid | 1 | 1988 | 2833 | 0.010 |
Why?
|
| Heart Failure | 2 | 2013 | 11840 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 2411 | 0.010 |
Why?
|
| Bone Density | 1 | 2007 | 3491 | 0.010 |
Why?
|
| Computer Graphics | 1 | 1994 | 344 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 3106 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 9347 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 2601 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39193 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1997 | 2910 | 0.010 |
Why?
|
| Risk-Taking | 1 | 1997 | 1021 | 0.010 |
Why?
|
| Employment | 1 | 1997 | 1106 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1998 | 1424 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 4526 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2000 | 1662 | 0.010 |
Why?
|
| Infant | 1 | 1992 | 36386 | 0.010 |
Why?
|
| HIV Infections | 1 | 1996 | 17533 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2002 | 3286 | 0.000 |
Why?
|
| ROC Curve | 1 | 1996 | 3620 | 0.000 |
Why?
|
| Primary Health Care | 1 | 2005 | 4736 | 0.000 |
Why?
|
| Thrombosis | 1 | 2002 | 2949 | 0.000 |
Why?
|
| Bone and Bones | 1 | 1998 | 2554 | 0.000 |
Why?
|
| Cardiomegaly | 1 | 1989 | 589 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 14751 | 0.000 |
Why?
|
| Blood Pressure Determination | 1 | 1990 | 647 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1997 | 5302 | 0.000 |
Why?
|
| Smoking | 1 | 2002 | 9081 | 0.000 |
Why?
|
| Diet | 1 | 2002 | 8086 | 0.000 |
Why?
|
| Length of Stay | 1 | 1997 | 6485 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 59889 | 0.000 |
Why?
|
| Neoplasms | 1 | 1991 | 22340 | 0.000 |
Why?
|
| Obesity | 1 | 2002 | 13076 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1995 | 42500 | 0.000 |
Why?
|